Literature DB >> 11876648

Nitric oxide activation of soluble guanylyl cyclase reveals high and low affinity sites that mediate allosteric inhibition by calcium.

Shiva Kazerounian1, Giovanni M Pitari, Inez Ruiz-Stewart, Stephanie Schulz, Scott A Waldman.   

Abstract

Cyclic GMP (cGMP) and Ca(2+) regulate opposing mechanisms in (patho)physiological processes reflected in the reciprocal regulation of their intracellular concentrations. Although mechanisms by which cGMP regulates [Ca(2+)](i) have been described, those by which Ca(2+) regulates [cGMP](i) are less well understood. In the present study, Ca(2+) inhibited purified sGC activated by sodium nitroprusside (SNP), a precursor of nitric oxide (NO), employing Mg-GTP as substrate in a concentration-dependent fashion, but was without effect on basal enzyme activity. Ca(2+) inhibited sGC stimulated by protoporphyrin IX or YC-1 suggesting that inhibition was not NO-dependent. In contrast, Ca(2+) was without effect on sGC activated by SNP employing Mn-GTP as substrate, demonstrating that inhibition did not reflect displacement of heme from sGC. Ligand activation of sGC unmasked negative allosteric sites of high (K(i) similar 10(-7) M) and low (K(i) approximately 10(-5) M) affinity for Ca(2+) that mediated noncompetitive and uncompetitive inhibition, respectively. Free Mg(2+) in excess of substrate did not alter the concentration-response relationship of Ca(2+) inhibition at high affinity sites, but produced a rightward shift in that relationship at low affinity sites. Similarly, Ca(2+) inhibition at high affinity sites was noncompetitive, whereas inhibition at low affinity sites was competitive, with respect to free Mg(2+). Purified sGC specifically bound (45)Ca(2+) in the presence of a 1000-fold excess of Mg(2+) and in the absence of activating ligands. These data suggest that sGC is a constitutive Ca(2+) binding protein whose allosteric function is conditionally dependent upon ligand activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11876648     DOI: 10.1021/bi0110894

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration.

Authors:  Saumya Ramanathan; Stacy Mazzalupo; Scott Boitano; William R Montfort
Journal:  Biochemistry       Date:  2011-08-16       Impact factor: 3.162

Review 2.  Redox signaling in cardiovascular health and disease.

Authors:  Nageswara R Madamanchi; Marschall S Runge
Journal:  Free Radic Biol Med       Date:  2013-04-11       Impact factor: 7.376

3.  Hyperpolarization-activated ion channels as targets for nitric oxide signalling in deep cerebellar nuclei.

Authors:  Gary W Wilson; John Garthwaite
Journal:  Eur J Neurosci       Date:  2010-06-01       Impact factor: 3.386

Review 4.  Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor.

Authors:  William R Montfort; Jessica A Wales; Andrzej Weichsel
Journal:  Antioxid Redox Signal       Date:  2016-04-26       Impact factor: 8.401

5.  Inhibition of nitric oxide-activated guanylyl cyclase by calmodulin antagonists.

Authors:  L R James; C H Griffiths; J Garthwaite; T C Bellamy
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

6.  Allostery in recombinant soluble guanylyl cyclase from Manduca sexta.

Authors:  Xiaohui Hu; Lauren B Murata; Andrzej Weichsel; Jacqueline L Brailey; Sue A Roberts; Alan Nighorn; William R Montfort
Journal:  J Biol Chem       Date:  2008-05-30       Impact factor: 5.157

7.  Nitric oxide stimulation of cGMP accumulation in myometrial cells from pregnant women is antagonized by oxytocin.

Authors:  Iain L O Buxton
Journal:  Proc West Pharmacol Soc       Date:  2008

Review 8.  Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow.

Authors:  Natasha M Rogers; Franziska Seeger; Elsa D Garcin; David D Roberts; Jeffrey S Isenberg
Journal:  Front Physiol       Date:  2014-04-04       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.